Pfiz­er and Val­neva's Ly­me dis­ease bet rolls on to PhI­II as more fi­nanc­ing flows their way

Pfiz­er’s core fo­cus on vac­cine de­vel­op­ment ex­tends well be­yond the Covid-19 fran­chise. Their bet on a Ly­me dis­ease can­di­date out of Val­ne­va is con­tin­u­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER